相似文献
1
Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitors.
Bioorg Med Chem Lett. 2011 Nov 15;21(22):6909-15. doi: 10.1016/j.bmcl.2011.06.116. Epub 2011 Jul 2.
2
Monosubstituted γ-lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors of β-secretase (BACE).
Bioorg Med Chem Lett. 2011 Nov 15;21(22):6916-24. doi: 10.1016/j.bmcl.2011.06.109. Epub 2011 Jun 30.
3
Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region.
Bioorg Med Chem Lett. 2010 Oct 15;20(20):6034-9. doi: 10.1016/j.bmcl.2010.08.070. Epub 2010 Aug 19.
4
Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors.
Bioorg Med Chem Lett. 2011 Apr 1;21(7):1942-7. doi: 10.1016/j.bmcl.2011.02.038. Epub 2011 Feb 15.
5
Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
J Neurochem. 2007 Feb;100(3):802-9. doi: 10.1111/j.1471-4159.2006.04260.x.
6
P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
J Pharmacol Exp Ther. 2008 Aug;326(2):502-13. doi: 10.1124/jpet.108.138974. Epub 2008 May 22.
7
Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors.
J Med Chem. 2010 Feb 11;53(3):942-50. doi: 10.1021/jm901472u.
8
Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents.
Bioorg Med Chem Lett. 2009 Nov 15;19(22):6386-91. doi: 10.1016/j.bmcl.2009.09.061. Epub 2009 Sep 19.
9
Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor.
Bioorg Med Chem Lett. 2008 Jan 1;18(1):418-22. doi: 10.1016/j.bmcl.2007.10.053. Epub 2007 Oct 18.
10
Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
J Med Chem. 2012 Nov 8;55(21):9224-39. doi: 10.1021/jm3009426. Epub 2012 Oct 8.
引用本文的文献
1
Advances in the Synthetic Approaches to β‑Secretase (BACE-1) Inhibitors in Countering Alzheimer's: A Comprehensive Review.
ACS Omega. 2025 Aug 6;10(32):35367-35433. doi: 10.1021/acsomega.5c04467. eCollection 2025 Aug 19.
2
BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease.
Chem Soc Rev. 2014 Oct 7;43(19):6765-813. doi: 10.1039/c3cs60460h.
3
The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors.
Curr Top Med Chem. 2013;13(15):1787-807. doi: 10.2174/15680266113139990137.
Zotero 插件